Associations Between Schizophrenia Polygenic Liability, Symptom Dimensions, and Cognitive Ability in Schizophrenia

Key Points Question Are phenotypic dimensions in schizophrenia associated with genetic liability to schizophrenia, other neuropsychiatric disorders, and intelligence? Findings In this cross-sectional genetic association study of 1220 individuals with schizophrenia, analyses indicated that higher levels of disorganized symptoms, but not other symptom dimensions, and lower levels of current cognitive ability were significantly associated with schizophrenia polygenic risk scores. Current cognitive ability was also associated with intelligence polygenic risk scores. Meaning The findings of this study suggest that variation in disorganized symptoms and cognitive ability in schizophrenia are markers of schizophrenia common genetic liability; cognitive performance in schizophrenia may reflect distinct contributions from genetic liabilities to both intelligence and schizophrenia.

[1]  R. Gentleman,et al.  SHARED AND DISTINCT GENETIC INFLUENCES BETWEEN COGNITIVE DOMAINS AND PSYCHIATRIC DISORDER RISK BASED ON GENOME-WIDE DATA , 2021, European Neuropsychopharmacology.

[2]  A. Rossi,et al.  Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. , 2021, JAMA psychiatry.

[3]  S. Scherer,et al.  Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome , 2020, Nature Medicine.

[4]  R. Gentleman,et al.  Shared and Distinct Genetic Influences Between Cognitive Domains and Psychiatric Disorder Risk Based on Genome-Wide Data , 2020, Biological Psychiatry.

[5]  S. Ripke,et al.  Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia , 2020, medRxiv.

[6]  Michael D. Gregory,et al.  Distinct Polygenic Score Profiles in Schizophrenia Subgroups With Different Trajectories of Cognitive Development. , 2019, The American journal of psychiatry.

[7]  D. Rujescu,et al.  The Relationship Between Polygenic Risk Scores and Cognition in Schizophrenia , 2019, Schizophrenia bulletin.

[8]  G. Kirov,et al.  Clinical indicators of treatment-resistant psychosis , 2019, The British Journal of Psychiatry.

[9]  A. Malhotra,et al.  Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders , 2019, bioRxiv.

[10]  John P. Rice,et al.  Identification of common genetic risk variants for autism spectrum disorder , 2019, Nature Genetics.

[11]  E. Granholm,et al.  The Latent Structure of Negative Symptoms in Schizophrenia , 2018, JAMA psychiatry.

[12]  R. Marioni,et al.  Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions , 2018, Nature Neuroscience.

[13]  Alicia R. Martin,et al.  Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder , 2018, Nature Genetics.

[14]  G. Breen,et al.  Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort , 2018, Translational Psychiatry.

[15]  Tyrone D. Cannon,et al.  Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence , 2018, Nature Genetics.

[16]  John P. Rice,et al.  Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. , 2018, Cell.

[17]  Nancy C. Andreasen,et al.  Scale for the Assessment of Positive Symptoms , 2018 .

[18]  S. Mccarroll,et al.  Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls , 2018, Translational Psychiatry.

[19]  M. Owen,et al.  Examining cognition across the bipolar/schizophrenia diagnostic spectrum. , 2018, Journal of psychiatry & neuroscience : JPN.

[20]  P. Lichtenstein,et al.  Genome‐wide analysis of adolescent psychotic‐like experiences shows genetic overlap with psychiatric disorders , 2018, bioRxiv.

[21]  Jakob Grove,et al.  Genome-wide association study identifies 30 Loci Associated with Bipolar Disorder , 2017, bioRxiv.

[22]  D. Rujescu,et al.  Genome-wide Association Study of Clinical Features in the Schizophrenia Psychiatric Genomics Consortium: Confirmation of Polygenic Effect on Negative Symptoms , 2017, bioRxiv.

[23]  Peter B. Jones,et al.  Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General Population. , 2016, JAMA psychiatry.

[24]  Jack Euesden,et al.  PRSice: Polygenic Risk Score software , 2014, Bioinform..

[25]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[26]  N. Wray,et al.  Research review: Polygenic methods and their application to psychiatric traits. , 2014, Journal of child psychology and psychiatry, and allied disciplines.

[27]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[28]  Michael F. Green,et al.  Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. , 2013, Journal of psychiatric research.

[29]  A F Terwisscha van Scheltinga,et al.  Schizophrenia genetic variants are not associated with intelligence , 2013, Psychological Medicine.

[30]  Jianxin Shi,et al.  Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. , 2012, The American journal of psychiatry.

[31]  Yves Rosseel,et al.  lavaan: An R Package for Structural Equation Modeling , 2012 .

[32]  P. McGuffin,et al.  Heritability estimates for psychotic symptom dimensions in twins with psychotic disorders , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[33]  J. McGrath,et al.  Familiality of novel factorial dimensions of schizophrenia. , 2009, Archives of general psychiatry.

[34]  R. Ophoff,et al.  The genetics of symptom dimensions of schizophrenia: Review and meta-analysis , 2008, Schizophrenia Research.

[35]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.

[36]  James B. Schreiber,et al.  Reporting Structural Equation Modeling and Confirmatory Factor Analysis Results: A Review , 2006 .

[37]  Nick Craddock,et al.  Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. , 2006, Archives of general psychiatry.

[38]  R. Murray,et al.  Twin study of symptom dimensions in psychoses , 2001, British Journal of Psychiatry.

[39]  R. Gonzalez,et al.  Difference score correlations in relationship research: A conceptual primer , 1999 .

[40]  P. McGuffin,et al.  Dimensions of psychosis in affected sibling pairs , 1998, Schizophrenia Research.

[41]  T. Brugha,et al.  SCAN. Schedules for Clinical Assessment in Neuropsychiatry. , 1990, Archives of general psychiatry.

[42]  N. Andreasen.  The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.

[43]  L. Krabbendam,et al.  ARE PSYCHOTIC PSYCHOPATHOLOGY AND NEUROCOGNITION ORTHOGONAL? A SYSTEMATIC REVIEW OF THEIR ASSOCIATIONS , 2008, Schizophrenia Research.

[44]  Frauke Schultze-Lutter,et al.  Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. , 2009, Schizophrenia bulletin.

[45]  W. Alexander.  American psychiatric association. , 2008, P & T : a peer-reviewed journal for formulary management.

[46]  P. McGuffin,et al.  Clinical variables and genetic loading for schizophrenia: analysis of published Danish adoption study data. , 2002, Schizophrenia bulletin.

[47]  P. Bentler,et al.  Cutoff criteria for fit indexes in covariance structure analysis : Conventional criteria versus new alternatives , 1999 .